HeartBeam, a developmental stage digital healthcare company with a proprietary ECG telemedicine technology for treating cardiovascular disease, closed its IPO of 2.75 million units. Each consists of one share and a warrant to purchase a share at $6. Stock and warrants were issued separately in this offering. The warrants are exercisable for five years after the issuance date. Stock and warrants trade on the Nasdaq under BEAT and BEATW.
The net proceeds to HeartBeam from the offering, deducting the underwriting discounts and commissions and offering expenses, amount to $14.9 million.
The Benchmark Company was sole book-running manager for the offering. Read more.
